The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. 
/dose daily; four total doses]), and intensification 3 (high-dose cytarabine and L-asparaginase). Of note, an echocardiogram was not repeated before the start of intensification 1. During intensification 1, the patient developed Streptococcus viridans sepsis, which required 4 days in the intensive care unit with antimicrobial and inotropic support. Repeat echocardiogram after recovery from the sepsis episode demonstrated low-normal LV systolic function (EF, 53%; SF, 27%), and she subsequently began intensification 2. On day 3 of intensification 2, the patient developed afebrile tachypnea, tachycardia, and an increasing oxygen requirement. Chest x-ray revealed cardiomegaly and pulmonary vascular congestion. Cardiac troponins were normal, whereas N-terminal pro B-type natriuretic peptide was 10 times the upper limit of normal. Repeat echocardiogram showed an enlarged LV with moderate to severely depressed LV function (EF, 28%; SF, 14%). Day 4 mitoxantrone was omitted and a cardiology consult obtained.
CHALLENGES IN DIAGNOSIS AND MANAGEMENT
Current pediatric acute myeloid leukemia (AML) therapy in the United States relies on an anthracycline-intensive backbone developed by the Medical Research Council of the United Kingdom and is associated with a 5-year survival rate of greater than 60%. [1] [2] [3] [4] However, the use of anthracyclines is limited by the risk cardiotoxicity that typically manifests as asymptomatic cardiac dysfunction (identified on imaging studies as abnormalities in left ventricular systolic dysfunction [LVSD] : low ejection fraction [EF] or shortening fraction [SF] ) and can evolve to symptomatic heart failure 5, 6 (Fig 1) . Outcomes after onset of clinical heart failure during cancer treatment are poor; some patients will have progressive disease that requires heart transplantation, whereas others may experience temporary recovery with subsequent decline in function. [5] [6] [7] LVSD can cause treatment interruptions or omission of potentially life-saving therapy in children with AML, which makes early detection or prevention an important therapeutic goal.
Anthracycline-related cardiotoxicity is characterized by alterations in cardiomyocyte morphology indicative of nonischemic cellular apoptosis. 5, 8, 9 The heart has an innate reserve capacity that allows it to endure a certain amount of cardiomyocyte loss. 5, 8, 9 Acute-onset LVSD and subsequent clinical heart failure during treatment occurs when this reserve is depleted, typically by multiple hits to the heart as a result of drugrelated factors (cumulative anthracycline dose, the use of other cardiotoxic therapies such as radiotherapy to the heart), clinical risk factors (female sex, black race), or extrinsic physiologic demands (uncontrolled hypertension, clinical sepsis). 5, 6, 8, 9 In patients with AML, bacterial sepsis is the leading cause of morbidity and mortality and accounts for 60% of the treatmentrelated mortality seen. 10 Gram-positive isolates such as Streptococcus viridans account for approximately one half of all documented cases of bacteremia followed by gram-negative isolates (with Pseudomonas aeruginosa and Klebsiella species predominating) and polymicrobial infections. 11, 12 The first challenge is to balance a treatment's potential for cure with its risk of adverse events. Anthracyclines are among the most effective agents in the treatment of AML and will likely remain the backbone of curative therapy for the foreseeable future. 1, 4 The introduction of newer agents such as gemtuzumab ozogamicin have resulted in modest improvements in event-free survival (EFS) and overall survival (OS), 2, 3 but this is still well below improvements in outcome seen in other hematologic malignancies such as acute lymphoblastic leukemia and nonHodgkin and Hodgkin lymphoma. As such, primordial prevention (eg, omitting or limiting the cumulative dose of anthracyclines; Table 1 ) is likely not an option for clinicians considering optimal treatment of children and adolescents with AML. In this population, primary prevention (limiting cardiotoxicity of the drug without affecting antitumor efficacy; Table 1 ) has not been explored effectively; most of our knowledge has to be extrapolated from other childhood and adult-onset cancer populations.
Dexrazoxane (ICRF-187) is the only agent approved by the US Food and Drug Administration to mitigate anthracyclineinduced cardiotoxicity. Its mechanisms of action include reduction of cardiotoxic reactive oxygen species, iron chelation, and topoisomerase II inhibition. 5, [13] [14] [15] Meta-analyses of randomized trial data have suggested that dexrazoxane decreases the risk of both clinical and asymptomatic heart failure during and shortly after therapy. 16, 17 Although data mostly are based on adult patients with breast cancer, at least two trials in children with acute lymphoblastic leukemia suggest that dexrazoxane may be effective at reducing the risk of acute cardiotoxicity without compromising the antitumor efficacy of anthracyclines. 18, 19 However, dexrazoxane is used in less than 10% of children with AML likely because its long-term efficacy is not known. 20 Alternative anthracycline dosing strategies, such as longer infusion time to minimize peak plasma concentrations, have not been shown to be effective for reducing LVSD risk in pediatric clinical trials. 21, 22 Liposomal formulations of common anthracyclines (doxorubicin, daunorubicin) offer a cardioprotective effect in adult cancer treatment, but no randomized studies in children have been done. 17, 23 Similarly, little is known about the cardiotoxic potential of nondoxorubicin anthracycline analogs, such as daunorubicin and mitoxantrone. 23 A recent study in 5-year survivors of childhood cancer indicated that daunorubicin may be 50% less cardiotoxic, 24 whereas mitoxantrone may be two times more cardiotoxic 25 than current long-term follow-up guidelines suggest, which has direct implications for the frequency and modality of lifelong surveillance in these survivors. 26 Studies are needed to examine the risks of acute cardiotoxicity with these agents, which would help to facilitate evidence-based recommendations for on-therapy monitoring; emerging preclinical models 6,27-29 could be leveraged to assess accurately the antitumor as well as the cardiotoxic potential of these analogs.
Finally, the role of cardiac surveillance in decisions about omission or discontinuation of anticancer therapy is hotly contested. In 1992, because of an increased recognition of the risk of cardiotoxicity associated with anthracyclines in children, Steinherz et al 30 proposed guidelines for monitoring children with echocardiography in conjunction with electrocardiography and/or radionuclide angiography during anthracycline-based therapy. Their recommendations were to discontinue anthracycline therapy if cardiac functional deterioration was found on two successive tests and confirmed by abnormalities seen on endomyocardial biopsy, if possible. Other investigators at the time noted that none of the studies cited in the guidelines prospectively evaluated the effects of cardiac monitoring and the adjustment of anthracycline dose on cancer-related outcomes, and they questioned whether the guidelines might do more harm than good because there was no evidence that the proposed screening process predicted either early or late cardiac events. 31 During the approximately three decades since, no studies have examined the relative benefit or harm of a clinical practice that has for the most part become a part of routine childhood cancer care.
SUMMARY OF THE RELEVANT LITERATURE
The study that accompanies this article by Getz et al 32 describes the incidence and natural history of LVSD in 1,022 pediatric patients with AML treated in the Children's Oncology Group trial AAML0531 (ClinicalTrials.gov identifier: NCT00372593) and examines the effect of LVSD on their EFS and OS. In the study, approximately 12% of patients developed LVSD over a 5-year follow-up, with greater than 70% of incident events occurring during onprotocol therapy (8% incidence of cardiotoxicity while on protocol). The highest course-specific risk occurred during intensification 2 (cytarabine and mitoxantrone) likely as a result of the increased risk of infection-associated cardiotoxicity. Of note, the risk was equally elevated in intensification 3, a nonanthracycline course, perhaps as a result of gradual depletion of cardiac functional reserves over time, which thus highlighted the need for close monitoring of cardiac function during each course of AML therapy regardless of course-specific anthracycline exposure. The observed rate of on-therapy cardiotoxicity differed from estimates reported in previous studies (range, 4.3% to 21.1%). [33] [34] [35] This may be a reflection of variances in cardiac outcome definitions (eg, objective echocardiographic parameters, symptombased common terminology of adverse events classification alone) [33] [34] [35] , differing monitoring schedules [33] [34] [35] , and exclusion of cardiotoxicity in the context of infection, 33, 34 which accounts for a substantial proportion of events in patients with AML.
Patients who developed LVSD had significantly worse EFS (hazard ratio [HR], 1.6) and OS (HR, 1.6), and the effect on EFS was comparable in those who developed LVSD in the absence (HR, 1.6) or presence (HR, 1.6) of infection. The absolute reduction in EFS rate (approximately 15%) and OS rate (approximately 15%) in patients with LVSD was far greater than the EFS benefit (6.3%) from the new agent gemtuzumab ozogamicin evaluated in the study. Of note, AAML0531 mandated that anthracyclines be withheld if a significant cardiac disease defined as SF less than 27% existed. Although the authors do not have information on the proportion of patients able to resume anthracyclines after cardiac function recovered, the implications are that treatment omission and/or interruption may have contributed to suboptimal outcomes in these patients. To our knowledge, this groundbreaking study is the first to measurably link adverse cardiac outcomes (regardless of etiology) and cancer-related outcomes and speaks to the importance of strategies to optimize cardiovascular and supportive care to improve cancer-related outcomes. Limited efficacy exists with other cardioprotectants (eg, amifostine, acetylcysteine, L-carnitine, coenzyme Q10).
Better supportive care (eg, infection control) to reduce the risk of hemodynamic instability during treatment
Aggressive antimicrobial prophylaxis can improve cancerrelated and overall survival in children with AML. No information exists on whether better infection control can also reduce the incidence of cardiotoxicity in children with AML.
Secondary prevention Early biomarker-based detection (eg, advanced cardiac imaging, blood biomarkers) and pharmacologic intervention
Randomized clinical trials are lacking to demonstrate clinically significant reduction in risk of cardiotoxicity in children or adults. Studies (eg, ANZCTR identifier: ACTRN12614000341628) in adult patients with cancer may inform future strategies for biomarker-based prevention in children.
Overall, there was modest (54%) adherence to protocolmandated echocardiographic evaluations, and the rates were lowest during off-protocol follow-up. 32 As such, the rate of LVSD reported in this study underestimates the true magnitude of risk that may not become apparent until these children enter adulthood. In fact, studies have consistently shown that the echocardiogram obtained in the year after completion of therapy is the most important predictor of future heart failure risk. 5, 36 The challenges to cardiac monitoring adherence are not unique to this study. In the decade that followed the 1992 Steinherz cardiac surveillance recommendations, 30 van Dalen et al 37 reported on adherence patterns for 11 protocols that required cardiac monitoring per the established guidelines and noted markedly inconsistent monitoring recommendations and variable criteria for stopping anthracycline treatment.
SUGGESTED APPROACHES TO MANAGEMENT

Accurately Identify Individuals at Risk for LVSD
Determination of LVSD and heart failure risk in children with a new diagnosis of AML can help to guide cancer treatment and cardiac surveillance during treatment. Efforts to date have focused primarily on risk prediction in long-term (. 5 years from diagnosis) survivors, and established models take into account both clinical (age at diagnosis, sex) and treatment-related (anthracycline dose, chest radiation) risk factors that accurately classify individuals into low, moderate, and high risk of heart failure by age 40 years. 38 That said, it is well established that marked individual variability exists in the prevalence and severity of heart failure in anthracycline-exposed children that is not explained exclusively by clinical and treatment-related risk factors alone. 39 Key germline genetic polymorphisms could result in differential risk for cardiotoxicity among long-term survivors with otherwise similar clinical and treatment-related risk factors. [40] [41] [42] [43] Studies are needed to integrate model building approaches developed in long-term survivors with emerging data on germline risk to characterize risk during cancer treatment accurately. This may help to identify subsets of patients in whom the risk of cardiotoxicity far outweighs the potential benefits associated with anthracyclinebased AML treatment regimens. Until then, more proactive integration of primary cardioprotection (eg, dexrazoxane, or liposomal anthracyclines) may be warranted for all children with AML.
Undertake Appropriate Early Screening and Cardiovascular Management
Current clinical practice is to monitor global measures of LV systolic function, such as EF and SF. 26 However these parameters are load dependent, have variable results, and do not accurately characterize early myocardial dysfunction that may occur during and shortly after anthracycline exposure. 5 Of note, LVSD can be irreversible after clinically significant decline in these parameters. 5, 7 Studies in adults with breast cancer have suggested that in patients with asymptomatic LVSD, time to initiation of pharmacologic therapy (eg, angiotensin-converting enzyme [ACE] inhibitors, b-blockers) is the most important predictor of longterm cardiac function recovery, 44, 45 which emphasizes the need to identify reliable cardiac biomarkers to guide clinical care. Advanced imaging modalities such as tissue characterization by cardiac magnetic resonance imaging 46, 47 and echocardiography-derived myocardial deformation imaging (strain) have been used to detect subclinical cardiac dysfunction in populations at risk for heart failure (eg, after myocardial infarction). 48, 49 When used in conjunction with blood biomarkers of cardiac injury and remodeling, these imaging biomarkers may be especially helpful for patients with cancer with borderline LV systolic function. To date, routine use of blood and imaging biomarkers in the asymptomatic oncology population remains limited primarily because of a lack of data to support improvement in cardiac and oncology outcomes. The ongoing Strain Surveillance During Chemotherapy for Improving Cardiovascular Outcomes trial is testing the use of early biomarkers in guiding pharmacologic intervention in adults with cancer, 50 and a similar study of biomarker-based intervention may be warranted for children at high risk for treatment-related LVSD.
Better Supportive Care During Cancer Treatment
Finally, the study by Getz et al 32 highlights the importance of comprehensive supportive care that extends beyond cardiovascular disease management in children with AML. One third of patients who developed LVSD on protocol had an associated infection at the time of their cardiac event. In these patients, more effective empirical and/or prophylactic antimicrobial strategies may be warranted to reduce both infection-related and cardiac morbidity. 51 Clinical suspicion for cardiac dysfunction should be high, and the threshold for cardiac evaluation should be low in any patient who is receiving potentially cardiotoxic therapy where intercurrent hemodynamic compromise exists.
CLINICAL RESOLUTION
In our case, the patient had multiple pediatric/adolescent risk factors for LVSD from anthracyclines, including female sex, black race, and development of borderline cardiac function after S viridans sepsis, a likely indicator of depleted cardiac reserves. Her case was discussed by the oncology and cardiology teams to determine the best ongoing course of therapy. Treatment with an ACE inhibitor was initiated. She completed intensification 3 with cytarabine and L-asparaginase and remains on an ACE inhibitor with borderline normal LV systolic function (EF, 45%; SF, 22%) 1 year after curative AML therapy.
